Wegovy Price Drop Exposes a Bigger Problem

Wegovy Price Drop Exposes a Bigger Problem

A major shift in obesity treatment is underway following a surprising pricing move that could change how patients access care. This episode explores the growing divide between traditional healthcare and alternative pathways, the real tradeoffs behind cost and safety, and what the future may hold for medications, access, and long term health.


TOPICS:

Wegovy Price Drop Changes EverythingWhat This Podcast CoversNew Savings Programs ExplainedWhy This Is Bigger Than PriceThe Broken Healthcare SystemRise of Telehealth & CompoundingThe New Parallel System of CareGray Market vs Medical AccessSafety vs Strength DebateRisks of Unregulated MedicationsWhy Long-Term Support MattersGray Market Supply ConcernsPharma Pressure & RegulationWhat Happens If Access ChangesTrust Issues with the System The Core Question: Safety or PowerAre OTC GLP-1s Coming?New Oral Drugs & NexboundWhy Pills Could Change EverythingAccess vs CareGLP-1s as Longevity DrugsEli Lilly’s Big Bet on the FutureThe Next 5–10 Years

Det här avsnittet är hämtat från ett öppet RSS-flöde och publiceras inte av Podme. Det kan innehålla reklam.

Avsnitt(207)

  We’re Solving Obesity. Now Who Pays for It?

We’re Solving Obesity. Now Who Pays for It?

This week on On The Pen, the GLP-1 story is moving in two very different directions.The Fifth Circuit handed FDA major wins in the fight over semaglutide and tirzepatide shortages, FDA updated its con...

2 Sep 24min

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 Coverage Is COLLAPSING in 2027

GLP-1 access is getting tighter just as obesity treatment is becoming more effective, more affordable, and more important to public health.In this episode of the On The Pen Podcast, Dave Knapp breaks ...

26 Aug 34min

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

$50 Zepbound Incoming? China Has US in a GLP-1 “Chokehold”

Could GLP-1 medications eventually cost just $40 to $50 per month? Hims & Hers CEO Andrew Dudum thinks so, and if he’s right, it could completely change access to obesity treatment in America.But gett...

18 Aug 45min

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

200 GLP-1 Deaths, Chrissy Metz & a Stunning Harvard Study

Https://www.otplinks.comBased on the transcript flow, here’s a clean YouTube description with chapter timestamps. The transcript itself doesn’t include timecodes, so these are estimated from speaking ...

12 Aug 31min

Eli Lilly Earnings Call Recap: Retatrutide News

Eli Lilly Earnings Call Recap: Retatrutide News

https://www.otplinks.com

7 Aug 59min

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk Warned us For Years About Synthesized Semaglutide. Now They Want In.

Novo Nordisk has spent years warning patients, regulators, lawmakers, and courts about the risks of synthetic semaglutide. Now, as patents begin to expire and China’s pharmaceutical industry becomes i...

4 Aug 18min

Retatrutide Biologic Battle: The Story Gets Bigger

Retatrutide Biologic Battle: The Story Gets Bigger

https://www.otplinks.comhttps://www.voafit.com/otpEpisode Referenced: https://www.youtube.com/watch?v=K8kaSoFCZ0c&t=41sThe retatrutide biologic fight is bigger than folks understand.This breakdown cov...

28 Juli 20min

GLP-1 Showdown: Inside The High Stakes War over Patients

GLP-1 Showdown: Inside The High Stakes War over Patients

Novo Nordisk just declared legal war on Eli Lilly as the battle over GLP-1 patients intensifies. But just because patients are being fought over does not mean they are being fought for.In this episode...

22 Juli 27min

Populärt inom Hälsa

somna-med-henrik
rss-jossan-nina
rss-bara-en-till-om-beroende-medberoende
bullfika
inga-beiga-morsor
rss-vuxna-pa-latsas
not-fanny-anymore
rss-viktmedicinpodden
angestpodden
sa-in-i-sjalen
sexnoveller-deluxe
johannes-hansen-podcast
rss-hos-psykologen
tyngre-traningssnack
sova-med-dan-horning
rss-basta-livet
halsorevolutionen
sex-pa-riktigt-med-marika-smith
rss-sjalsligt-avkladd
rss-angra-inget-3